Dr. MONIKA LAMBA SAINI joins Dr. Mark Gramling for a broader discussion beyond the usual trial-focused topics in this episode. This time, they explore the world of pathology and the latest technological advancements.

Key points include:

• The clinical applications of technology in pathology, where Dr. Monika shares insights from her experience in both molecular and digital pathology.
• How AI is playing a role in diagnostic applications and how pathologists work and improve patient outcomes.

Dr. Monika Lamba Saini, MBBS, MD, Ph.D., is the ‘Global Translational Pathology leader’ at ADC Therapeutics, where she is responsible for the scientific strategy, including the development and implementation of translational tissue-based biomarkers and using digital pathology as a tool to expedite the development pipeline. She previously served as the Director of Digital Pathology Innovation at Q2 Solutions, IQVIA, Edinburgh, where she provided stewardship of digital pathology from validation to implementation of the digital pathology systems, as well as providing pathology support for AI-based algorithms and digital image analyses. She is a pathologist-scientist with 20+ years of experience and proficiency in pathology. She comes with extensive experience in oncopathology, molecular pathology, and digital pathology with her PhD at the Université catholique de Louvain, Brussels, Belgium. She has been the principal investigator and sub-investigator of clinical trials for companion diagnostics in oncology with Cell Carta Belgium. Her experience spans across different countries and continents. She is the author and reviewer of many publications, including Lancet and Nature, and an invited speaker on international platforms. Professional interests include translational research, cancer biology, immunopathology, digital pathology, project design and management, medical writing/publications and public speaking.

Tune in to hear how these developments are shaping the future of pathology and clinical diagnostics.

In this episode of the LARVOL Onco Data Podcast, Bruno Larvol and Dr. Mark Gramling dive into key findings from ASTRO 2024. They explore some of the top insights presented at the conference, analyzing their impact and the reaction across social media and within the oncology community. Listeners will also learn how LARVOL CLIN offers insights through data analytics and social media response tracking for conferences like ASTRO. If you're involved in oncology research or pharma, this episode is packed with ways to make the most of conference data and highlights how you can explore these tools for your next event.

In this engaging episode of the LARVOL Onco Data Podcast, Guru Sonpavde, MD, and Dr. Amol Akhade delve into key takeaways from the latest oncology discussions at ESMO24. The conversation highlights the expanding treatment options for physicians. Our VP of Oncology, Dr. Mark Gramling, emphasized the importance of focusing on the optimal sequencing of treatments like Ambassador, Niagara, EV-302, and Litespark. While more study is needed to determine the best approach, having these additional options is a win for patient care. Dr. Guru shares his thoughts on these important trials and how they have shaped recent discussions in GU cancer research. Dr. Amol adds his perspective on the significance of these trials and the need for continued research. As the episode wraps up, both experts emphasize the value of ongoing collaboration and research, promising more in-depth discussions in the future. Don’t miss out on this lively exchange of insights into the latest advancements in urologic oncology! Check out clin.larvol.com for more oncology data, and don’t forget to follow Dr. Guru and Dr. Amol on social media for updates on future trials. #ESMO24 #GUOncology #AmbassadorTrial #NiagaraTrial #EV302 #Litespark #Oncology #LARVOL